{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:33:00Z","timestamp":1790386380886,"version":"4.1.0"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"vor","delay-in-days":952,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dupilumab [a monoclonal antibody blocking the shared receptor subunit for interleukin (IL)-4 and IL-13] is approved for patients aged \u2265 12 years with inadequately controlled, moderate-to-severe atopic dermatitis (AD). Dupilumab trials of up to 52 weeks demonstrated efficacy and a favourable safety profile in patients with moderate-to-severe AD inadequately controlled with topical medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To further characterize the safety of dupilumab by evaluating clinical laboratory findings from three randomized, double-blinded, placebo-controlled phase III trials (LIBERTY AD SOLO 1 &amp; 2 and LIBERTY AD CHRONOS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were randomized 1 : 1 : 1 (SOLO 1 &amp; 2) or 3 : 1 : 3 (CHRONOS) for 16 and 52 weeks, respectively, to dupilumab weekly, every 2 weeks or placebo. CHRONOS patients received a standardized concomitant topical corticosteroid regimen. Laboratory outcomes were summarized descriptively in 1376 patients from SOLO 1 &amp; 2 and 740 from CHRONOS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Treatment groups had similar results in baseline laboratory parameters. Platelets and neutrophils showed mild decreases from baseline in dupilumab vs. placebo groups. Some dupilumab-treated patients had small transient increases in eosinophils. Grade 3 eosinophilia was reported in &amp;lt; 1% of dupilumab-treated and placebo-treated patients; no adverse events were associated with eosinophilia. Lactate dehydrogenase levels decreased from baseline during dupilumab treatment in all trials. No clinically meaningful changes were observed between treatment groups in other haematology, chemistry or urinalysis parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There were no clinically important changes in routine laboratory parameters that could be attributed to dupilumab. This study supports the use of dupilumab as a systemic treatment for moderate-to-severe AD that does not require laboratory monitoring.<\/jats:p>\n                    <jats:p>What's already known about this topic?<\/jats:p>\n                    <jats:p>Long-term treatment of atopic dermatitis (AD) with conventional immunosuppressive agents is limited by the risk of significant side-effects and a need for repeated tests to monitor haematological and\/or organ (e.g. liver, kidney) toxicities. Dupilumab [a monoclonal antibody blocking the shared receptor subunit for interleukin (IL)-4 and IL-13] is approved for the treatment of patients with inadequately controlled, moderate-to-severe AD. In 16-week and 52-week studies, dupilumab demonstrated a positive risk\/benefit profile in moderate-to-severe AD.<\/jats:p>\n                    <jats:p>What does this study add?<\/jats:p>\n                    <jats:p>This study is the first comprehensive analysis of dupilumab laboratory safety data of the 16-week SOLO 1 &amp; 2 (pooled N = 1376) and 52-week CHRONOS (N = 740) trials, demonstrating an absence of clinically important changes in haematology, serum chemistry and urinalysis parameters in patients with moderate-to-severe AD treated with dupilumab. Our data support the use of dupilumab as a systemic treatment for the long-term management of moderate-to-severe AD without routine laboratory monitoring in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bjd.18434","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T04:09:06Z","timestamp":1565669346000},"page":"1120-1135","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":130,"title":["Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)"],"prefix":"10.1093","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0177-8722","authenticated-orcid":false,"given":"A.","family":"Wollenberg","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergology Ludwig Maximilian University of Munich Frauenlobstra\u00dfe 9\u201311 80337 Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.A.","family":"Beck","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Rochester Medical Center Rochester NY U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2633-985X","authenticated-orcid":false,"given":"A.","family":"Blauvelt","sequence":"additional","affiliation":[{"name":"Oregon Medical Research Center Portland OR U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.L.","family":"Simpson","sequence":"additional","affiliation":[{"name":"Department of Dermatology Oregon Health & Science University Portland OR U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Chen","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown NY U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Chen","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown NY U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Shumel","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown NY U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.A.","family":"Khokhar","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown NY U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Hultsch","sequence":"additional","affiliation":[{"name":"Sanofi Genzyme Cambridge MA U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Rizova","sequence":"additional","affiliation":[{"name":"Sanofi Genzyme Cambridge MA U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5345-678X","authenticated-orcid":false,"given":"A.B.","family":"Rossi","sequence":"additional","affiliation":[{"name":"Sanofi Genzyme Cambridge MA U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.M.H.","family":"Graham","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown NY U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pirozzi","sequence":"additional","affiliation":[{"name":"Sanofi Bridgewater NJ U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Lu","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown NY U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ardeleanu","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown NY U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,1]]},"reference":[{"key":"2023083116104905700_bjd18434-bib-0001","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/jdv.13599","article-title":"ETFAD\/EADV eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients","volume":"30","author":"Wollenberg","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023083116104905700_bjd18434-bib-0002","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","article-title":"Guidelines of care for the management of atopic dermatitis: Section 1. Diagnosis and assessment of atopic dermatitis","volume":"70","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2023083116104905700_bjd18434-bib-0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2023083116104905700_bjd18434-bib-0004","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s12016-016-8548-5","article-title":"Bacterial and viral infections in atopic dermatitis: a comprehensive review","volume":"51","author":"Ong","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"2023083116104905700_bjd18434-bib-0005","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jid.2017.01.030","article-title":"Increased risk of cutaneous and systemic infections in atopic dermatitis \u2013 a cohort study","volume":"137","author":"Langan","year":"2017","journal-title":"J Invest Dermatol"},{"key":"2023083116104905700_bjd18434-bib-0006","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.anai.2017.10.019","article-title":"Association between atopic dermatitis and serious cutaneous, multiorgan and systemic infections in US adults","volume":"120","author":"Narla","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2023083116104905700_bjd18434-bib-0007","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/jdv.14891","article-title":"Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: Part I","volume":"32","author":"Wollenberg","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023083116104905700_bjd18434-bib-0008","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.anai.2017.10.039","article-title":"Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape","volume":"120","author":"Boguniewicz","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2023083116104905700_bjd18434-bib-0009","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jaip.2012.09.002","article-title":"Atopic Dermatitis Working Group of the Allergic Skin Diseases Committee of the AAAAI. Management of difficult-to-treat atopic dermatitis","volume":"1","author":"Arkwright","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2023083116104905700_bjd18434-bib-0010","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/bjd.15928","article-title":"Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement","volume":"178","author":"Drucker","year":"2018","journal-title":"Br J Dermatol"},{"key":"2023083116104905700_bjd18434-bib-0011","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaci.2013.07.049","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review","volume":"133","author":"Roekevisch","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"2023083116104905700_bjd18434-bib-0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13555-016-0170-1","article-title":"Systemic treatment of adult atopic dermatitis: a review","volume":"7","author":"Megna","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2023083116104905700_bjd18434-bib-0013","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1468-3083.2012.04636.x","article-title":"Guidelines for treatment of atopic eczema (atopic dermatitis). Part II","volume":"26","author":"Ring","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023083116104905700_bjd18434-bib-0014","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents","volume":"71","author":"Sidbury","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2023083116104905700_bjd18434-bib-0015","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdv.14888","article-title":"Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: Part II","volume":"32","author":"Wollenberg","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023083116104905700_bjd18434-bib-0016","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1073\/pnas.1323896111","article-title":"Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes","volume":"111","author":"Macdonald","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023083116104905700_bjd18434-bib-0017","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice","volume":"111","author":"Murphy","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023083116104905700_bjd18434-bib-0018","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"2023083116104905700_bjd18434-bib-0019","volume-title":"Highlights of prescribing information","author":"DUPIXENT\u00ae (dupilumab)"},{"key":"2023083116104905700_bjd18434-bib-0020","volume-title":"Summary of Product Characteristics","author":"Dupixent (dupilumab)"},{"key":"2023083116104905700_bjd18434-bib-0021","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"2023083116104905700_bjd18434-bib-0022","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"2023083116104905700_bjd18434-bib-0023","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jdermsci.2019.02.002","article-title":"Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)","volume":"94","author":"Tha\u00e7i","year":"2019","journal-title":"J Dermatol Sci"},{"key":"2023083116104905700_bjd18434-bib-0024","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"2023083116104905700_bjd18434-bib-0025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet"},{"key":"2023083116104905700_bjd18434-bib-0026","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","article-title":"Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9)","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"key":"2023083116104905700_bjd18434-bib-0027","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2023083116104905700_bjd18434-bib-0028","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N Engl J Med"},{"key":"2023083116104905700_bjd18434-bib-0029","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"2023083116104905700_bjd18434-bib-0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"2023083116104905700_bjd18434-bib-0031","author":"Hirano","year":"2019","journal-title":"Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis"},{"key":"2023083116104905700_bjd18434-bib-0032","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"2023083116104905700_bjd18434-bib-0033","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"key":"2023083116104905700_bjd18434-bib-0034","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40257-019-00445-7","article-title":"Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis","volume":"20","author":"Eichenfield","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"2023083116104905700_bjd18434-bib-0035","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/DHPS.S28801","article-title":"Clinical use of anti-TNF therapy and increased risk of infections","volume":"5","author":"Ali","year":"2013","journal-title":"Drug Healthc Patient Saf"},{"key":"2023083116104905700_bjd18434-bib-0036","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"key":"2023083116104905700_bjd18434-bib-0037","volume-title":"US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research"},{"key":"2023083116104905700_bjd18434-bib-0038","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.2353\/ajpath.2007.060881","article-title":"The role of platelets in leukocyte recruitment in chronic contact hypersensitivity induced by repeated elicitation","volume":"170","author":"Tamagawa-Mineoka","year":"2007","journal-title":"Am J Pathol"},{"key":"2023083116104905700_bjd18434-bib-0039","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jdermsci.2008.08.019","article-title":"Platelets as versatile regulators of cutaneous inflammation","volume":"53","author":"Katoh","year":"2009","journal-title":"J Dermatol Sci"},{"key":"2023083116104905700_bjd18434-bib-0040","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jaci.2012.06.044","article-title":"Comparative transcriptomic analyses of atopic dermatitis and psoriasis reveal shared neutrophilic inflammation","volume":"130","author":"Choy","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"2023083116104905700_bjd18434-bib-0041","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s12098-012-0810-0","article-title":"Circulating immunoglobulins, leucocytes and complements in childhood-onset atopic eczema","volume":"80","author":"Hon","year":"2013","journal-title":"Indian J Pediatr"},{"key":"2023083116104905700_bjd18434-bib-0042","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jdermsci.2014.10.003","article-title":"Important roles of platelets as immune cells in the skin","volume":"77","author":"Tamagawa-Mineoka","year":"2015","journal-title":"J Dermatol Sci"},{"key":"2023083116104905700_bjd18434-bib-0043","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0065-2776(08)01003-1","article-title":"Biology of the eosinophil","volume":"101","author":"Blanchard","year":"2009","journal-title":"Adv Immunol"},{"key":"2023083116104905700_bjd18434-bib-0044","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1365-2230.1990.tb02086.x","article-title":"Blood eosinophilia in atopic dermatitis","volume":"15","author":"Uehara","year":"1990","journal-title":"Clin Exp Dermatol"},{"key":"2023083116104905700_bjd18434-bib-0045","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000247419","article-title":"Correlation of eosinophils, eosinophil cationic protein and soluble interleukin-2 receptor with the clinical activity of atopic dermatitis","volume":"185","author":"K\u00e4gi","year":"1992","journal-title":"Dermatology"},{"key":"2023083116104905700_bjd18434-bib-0046","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1046\/j.1365-2133.2001.04456.x","article-title":"Tissue eosinophilia in acute and chronic atopic dermatitis: a morphometric approach using quantitative image analysis of immunostaining","volume":"145","author":"Kiehl","year":"2001","journal-title":"Br J Dermatol"},{"key":"2023083116104905700_bjd18434-bib-0047","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s12016-011-8252-4","article-title":"IgE, mast cells, and eosinophils in atopic dermatitis","volume":"41","author":"Liu","year":"2011","journal-title":"Clin Rev Allergy Immunol"},{"key":"2023083116104905700_bjd18434-bib-0048","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.iac.2015.05.005","article-title":"Eosinophilia in dermatologic disorders","volume":"35","author":"de Graauw","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"key":"2023083116104905700_bjd18434-bib-0049","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jaci.2016.06.010","article-title":"Cellular and molecular immunologic mechanisms in patients with atopic dermatitis","volume":"138","author":"Werfel","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2023083116104905700_bjd18434-bib-0050","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"2023083116104905700_bjd18434-bib-0051","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1081-1206(10)61311-7","article-title":"CC chemokines and transmigration of eosinophils in the presence of vascular cell adhesion molecule 1","volume":"94","author":"Yamamoto","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2023083116104905700_bjd18434-bib-0052","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.4049\/jimmunol.148.4.1086","article-title":"IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1","volume":"148","author":"Schleimer","year":"1992","journal-title":"J Immunol"},{"key":"2023083116104905700_bjd18434-bib-0053","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.0022-202X.2005.23841.x","article-title":"Chemokines: key players in innate and adaptive immunity","volume":"125","author":"Esche","year":"2005","journal-title":"J Invest Dermatol"},{"key":"2023083116104905700_bjd18434-bib-0054","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3389\/fmed.2017.00139","article-title":"Interleukin-13 in asthma and other eosinophilic disorders","volume":"4","author":"Doran","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"2023083116104905700_bjd18434-bib-0055","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis","volume":"134","author":"Hamilton","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"2023083116104905700_bjd18434-bib-0056","first-page":"A5555","article-title":"Broader impact of IL-4R\u03b1 blockade than IL-5 blockade on mediators of type 2 inflammation and lung pathology in a house dust mite-induced asthma mouse model","volume":"199","author":"Allinne","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl. 62","key":"2023083116104905700_bjd18434-bib-0057","first-page":"PA977","article-title":"Blocking IL-4R\u03b1 with dupilumab prevents lung inflammation in a mouse asthma model","volume":"52","author":"Orengo","year":"2018","journal-title":"Eur Respir J"},{"key":"2023083116104905700_bjd18434-bib-0058","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4049\/jimmunol.165.1.108","article-title":"Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity","volume":"165","author":"Webb","year":"2000","journal-title":"J Immunol"},{"key":"2023083116104905700_bjd18434-bib-0059","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1442-200X.2009.02908.x","article-title":"Changes in serum lactate dehydrogenase activity in children with atopic dermatitis","volume":"52","author":"Morishima","year":"2010","journal-title":"Pediatr Int"},{"key":"2023083116104905700_bjd18434-bib-0060","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/ACI.0000000000000198","article-title":"Biomarkers for atopic dermatitis: a systematic review and meta-analysis","volume":"15","author":"Thijs","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"2023083116104905700_bjd18434-bib-0061","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.jid.2018.03.1517","article-title":"Patients with atopic dermatitis colonized with Staphylococcus aureus have a distinct phenotype and endotype","volume":"138","author":"Simpson","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2023083116104905700_bjd18434-bib-0062","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1346-8138.1990.tb01679.x","article-title":"Significance of elevated serum LDH (lactate dehydrogenase) activity in atopic dermatitis","volume":"17","author":"Mukai","year":"1990","journal-title":"J Dermatol"},{"key":"2023083116104905700_bjd18434-bib-0063","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00403-011-1198-9","article-title":"Association of serum interleukin-18 and other biomarkers with disease severity in adults with atopic dermatitis","volume":"304","author":"Kou","year":"2012","journal-title":"Arch Dermatol Res"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.18434","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjd.18434","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjd.18434","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/182\/5\/1120\/51317193\/bjd1120.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/182\/5\/1120\/51317193\/bjd1120.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T12:27:28Z","timestamp":1693484848000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/182\/5\/1120\/6603157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":63,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5,1]]},"published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.18434","relation":{},"ISSN":["1365-2133","0007-0963"],"issn-type":[{"value":"1365-2133","type":"electronic"},{"value":"0007-0963","type":"print"}],"subject":[],"published-other":{"date-parts":[[2020,5,1]]},"published":{"date-parts":[[2020,5,1]]},"assertion":[{"value":"2019-08-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}